Abstract
The initiation of the Committee for Proprietary Medicinal Products (CPMP) is set down in the EEC directive 75/319. The purpose of the CPMP is to facilitate the adoption of a common position by the member states with regard to decisions on the issuing of marketing authorizations and promoting thereby the free movements of proprietary medicinal products. The history and the functioning of the CPMP will be discussed. The development in the CPMP procedure on the first of November this year and the future trends will be presented. Special attention will be given to future steps of procedures concerning the free movements of proprietary medicinal products in Europe, not only the steps of the EEC-Commission, but also possible other steps, not yet initiated by the Commission will be discussed.
Get full access to this article
View all access options for this article.